CYP19A1 and endometrial cancer: In order to avoid resistance to endocrine therapy, we recently evaluated safety and efficacy of combining the aromatase inhibitor Anastrozole with the mTOR inhibitor Vistusertib, in 73 patients with advanced or relapsed HR+ endometrial cancer maximally treated with one line of chemotherapy [4].